Compare NetFlix Inc (NFLX) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetFlix Inc vs Organon & Co. Common Stock — how do they compare? NetFlix Inc trades at $71.2 (market cap $293.85B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: NetFlix Inc is far larger — about 81.4× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while NetFlix Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold NetFlix Inc for 126 Days and Organon & Co. Common Stock for 0 Days on average.
| NFLX | OGN | |
|---|---|---|
Market Cap | $293.85B | $3.61B |
Volume | 39,920,482 | 1,808,049 |
Sector | Media | Health |
52-Week High | $124.13 | $13.81 |
52-Week Low | $67.06 | $5.70 |
Typical Hold Time | 126 Days | 0 Days |
Enterprise Value | $299.03B | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Netflix (NFLX) trades at $70.48, down 0.18% on the day, with a bearish technical signal from moving averages. The company reported strong fundamentals with Q2 2026 EPS of $0.80 beating expectations, revenue of $45.18B in 2025, and a net income margin of 28.22%. Recent news highlights strategic moves into live sports and content expansion, while analyst consensus remains bullish with a $89.39 price target.
The outlook for NFLX is positive due to robust earnings growth and expanding profitability, but risks include competitive pressures and market volatility. The stock offers potential upside based on analyst targets, supported by strong cash flow and institutional interest, though investors should monitor execution on live content initiatives.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
